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Abstract
Background: Extra-cellular roles of Tat might be the main cause of maintenance of HIV-1 infected
CD4 T cells or reservoir cells. We developed a synthetic vaccine based on a Tat variant of 101
residues called Tat Oyi, which was identified in HIV infected patients in Africa who did not progress
to AIDS. We compared, using rabbits, different adjuvants authorized for human use to test on
ELISA the recognition of Tat variants from the five main HIV-1 subtypes. A formulation was tested
on macaques followed by a SHIV challenge with a European strain.
Results: Tat Oyi with Montanide or Calcium Phosphate gave rabbit sera able to recognize all Tat
variants. Five on seven Tat Oyi vaccinated macaques showed a better control of viremia compared
to control macaques and an increase of CD8 T cells was observed only on Tat Oyi vaccinated
macaques. Reservoir cells were not detectable at 56 days post-challenge in all Tat Oyi vaccinated
macaques but not in the controls.
Conclusion: The Tat Oyi vaccine should be efficient worldwide. No toxicity was observed on
rabbits and macaques. We show in vivo that antibodies against Tat could restore the cellular
immunity and make it possible the elimination of reservoir cells.
Background
The HIV-1 Tat protein plays important roles in the virus
life cycle and maintenance of HIV-1 infected CD4+ T cells
[1,2]. It is a trans-activating regulatory protein that stimu-
lates efficient transcription of the viral genome, which
requires structural changes of Tat to bind to a RNA stem-
loop structure called TAR [3,4]. However, Tat differs from
other HIV-1 regulatory proteins because it is rapidly
secreted by CD4+ T cells following HIV-1 infection, and
extra-cellular Tat is suspected to be directly involved in the
collapse of the cellular immune response against HIV-
infected cells [2] and directly contributes to the pathology
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of AIDS [5]. Extra-cellular Tat inhibits macrophage
responses by binding to the Fas ligand membrane recep-
tor [6] and inhibits cytotoxic T cell (CTL) responses due to
its ability to cross cell membranes and induce apoptosis of
uninfected T cells [7,8] via interaction with tubulin [8-10].
In addition, a number of studies have shown that the pres-
ence of antibodies against Tat blocks the replication of
HIV-1 in vitro and is related to non-progression to AIDS
[11-13]. Moreover, it has been shown that a HIV-1 Tat-
specific cytotoxic T lymphocyte response is inversely cor-
related with rapid progression to AIDS [14]. Further stud-
ies have emphasized the hypothesis that anti-Tat CTLs are
important in controlling virus replication early after pri-
mary infection [14,15].
The discovery of the extra-cellular functions of Tat in the
inhibition of the cellular immune response against HIV-
infected cells constitute the rationale to develop a vaccine
against HIV targeting Tat [16]. However, the development
of a Tat vaccine may face the same problems encountered
with HIV-1 envelope proteins as Tat exists in different
sizes (86 to 101 residues) and mutations exist that induce
structural heterogeneity [17]. The 2D NMR studies of two
active Tat variants from Europe and Africa confirmed this
structural heterogeneity, although a similar folding
appears to exist among Tat variants [18-20]. Currently,
there are five main HIV-1 subtypes in the world: subtypes
A (25 %) and C (50 %) are predominant and are found
mainly in Africa, India and South America; subtype B (12
%) is found mainly in Europe and North-America; sub-
type D (6%) is found in Africa and subtype E (4 %)(a
recombinant form known as CRF_01AE), is found mainly
in South East Asia [21]. Tat variability follows this geo-
graphical diversity with mutations of up to 38 % observed
among Tat variants from A, B, C, D and E HIV-1 subtypes
that do not alter Tat functions but do not allow cross rec-
ognition with Tat antibodies [22].
Up to now, the two main vaccine strategies against Tat use
a recombinant protein corresponding to a short 86 resi-
due version of a subtype-B European Tat variant that is
either inactivated [11] or has full activity [23]. These two
approaches were tested on macaques followed by a
homologous SHIV challenge [24,25]. A significant
decrease of viremia was observed in these two studies car-
ried out respectively on Cynomolgus [24] and Rhesus
macaques [25], without showing complete protection
during primary infection. A recent study showed long
term control of infection following homologous SHIV
challenge on Tat-vaccinated Cynomolgus macaques [26].
However, immunization with a subtype B Tat variant of
86 residues does not stimulate an efficient response
against subtype A and C Tat variants [27]. Moreover, most
Tat variants found in the field are of 101 residues [4].
Over the last 20 years, several HIV vaccine studies have
been tested using a homologous SHIV/macaque model
and some have met with success [28]. However, these
were not followed by success in clinical trials [29], possi-
bly due to the high genetic diversity of HIV-1. This is why
heterologous SHIV challenge in macaques, using a genet-
ically distinct virus, is now recommended to determine if
a vaccine can be effective against HIV-1 infection in
humans and corresponds to the most significant in vivo
experiment after clinical trials [28].
The interest to develop a Tat vaccine rose with the discov-
ery that seropositive long-term non-Progressor (LTNP)
patients had a higher level of Tat antibodies than seropos-
itive Rapid Progressor (RP) patients [13]. However, LTNP
patients are unable to eradicate HIV since they still have
HIV released from reservoir cells. Another category of
patients, the highly exposed persistently seronegative
(HEPS), appears to be more interesting since they were in
contact with the virus, they have developed a strong cyto-
toxic T lymphocyte (CTL) response against viral proteins
and have retro converted to become seronegative [30].
There is a very low prevalence of HEPS among adults and
it could be possible that the HEPS phenotype is due to
innate immunity [31].
Although HEPS patients have normally no detectable
virus, it was possible to isolate and clone a HIV-1 strain
from patients in a cohort in Gabon [32] that could be now
classified as HEPS. This strain called HIV-1 Oyi has genes
similar to regular HIV-1 strains except the tat gene, which
had mutations never found in other Tat variants [16]. The
epidemiological survey was carried out on a sample of
750 pregnant women and 25 were identified as seroposi-
tive [32]. From these 25 seropositive women, 23 rapidly
retro converted and became HEPS. All the HEPS women
were infected with HIV-1 Oyi. The high proportion of
HEPS phenotype in this cohort (92%) indicated that the
retro conversion was probably due to an acquired immu-
nity and not an innate immunity. Ten years after the pub-
lication of this epidemiological survey, the 23 women
were in good health and the HIV was no longer detectable
in their blood [22]. Immunization with Tat Oyi raises
antibodies in rabbits that are able to recognize different
Tat variants even with mutations of up to 38 %, which is
not possible with other Tat variants [22]. Tat Oyi appears
to induce a humoral immune response against three-
dimensional epitopes that are conserved in Tat variants in
spite of 38% mutations [22]. Moreover, Tat Oyi has a sim-
ilar structure to active Tat but is unable to trans-activate
[20].
This study is the first step of pre-clinical studies of a vac-
cine using a synthetic protein of 101 residues. Synthetic
vaccines are developed for many years because they couldRetrovirology 2006, 3:8 http://www.retrovirology.com/content/3/1/8
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be safer regarding biological vaccines, i e vaccines made
from inactivated pathogens or recombinant proteins.
However, most of the vaccines commercially available up
to now have a biological origin. Very few synthetic vac-
cines were able to demonstrate their efficacy in vivo against
a pathogen such as bacteria or virus due to the short size
of the peptides that can constitute only linear epitopes,
while 3D epitopes are the most susceptible to trigger an
immune response that neutralize a pathogen. This is why,
one of the objective of this study was to determine a vac-
cine formulation suitable for human use to prepare clini-
cal trials, as a previous study with Tat Oyi was carried out
using complete Freund adjuvant [22]. We evaluated the
antibody responses raised in rabbits by Tat Oyi comple-
mented with adjuvants authorized for human use and we
determined formulations providing similar results previ-
ously obtained with the Freund adjuvant [22]. Vaccina-
tion with Tat Oyi on seven Rhesus macaques provided an
excellent model to test in vivo the efficacy of this synthetic
vaccine before clinical trials. Furthermore, the vaccinated
Table I: Titre of pooled rabbit sera against different Tat variants (60 and 90 days post-inoculation)
Montanide ISA720 J60 Montanide ISA720 J90 Preimmune
titre mean SD titre mean SD titre mean SD
Oyi 128,000 6,700E-02 1,500E-03 128,000 7,000E-02 2,646E-03 320 6,733E-02 2,082E-03
Ug11RP 16,000 6,867E-02 1,443E-03 16,000 6,867E-02 2,309E-03 160 6,867E-02 1,155E-03
Eli 32,000 7,017E-02 1,041E-03 64,000 7,000E-02 1,000E-03 160 7,200E-02 2,000E-03
96Bw 8,000 7,400E-02 3,279E-03 16,000 6,933E-02 5,774E-04 320 8,000E-02 6,000E-03
CM240 32,000 6,683E-02 5,774E-04 1,000 6,600E-02 1,732E-03 320 6,767E-02 1,155E-03
HXB2 64,000 6,233E-02 1,041E-03 16,000 6,844E-02 2,143E-03 160 6,033E-02 2,887E-03
Aluminium Hydroxide J60 Aluminium Hydroxide J90 Preimmune
titre mean SD titre mean SD titre mean SD
Oyi 64,000 6,700E-02 8,660E-04 16,000 6,767E-02 2,082E-03 80 6,700E-02 8,660E-04
Ug11RP 16,000 6,850E-02 5,000E-04 2,000 6,700E-02 9,313E-10 160 6,850E-02 5,000E-04
Eli 64,000 6,550E-02 9,313E-10 8,000 6,533E-02 5,774E-04 160 6,550E-02 9,313E-10
96Bw 32,000 7,167E-02 2,887E-04 1,000 6,733E-02 1,528E-03 160 7,167E-02 2,887E-04
CM240 32,000 6,967E-02 7,638E-04 1,000 6,633E-02 5,774E-04 80 6,967E-02 7,638E-04
HXB2 64,000 6,650E-02 1,000E-03 16,000 6,500E-02 1,000E-03 160 6,650E-02 1,000E-03
Calcium Phosphate Gel J90 Preimmune
titre mean SD titre mean SD
Oyi 32,000 8,033E-02 1,528E-03 160 6,700E-02 2,887E-03
Ug11RP 16,000 6,750E-02 2,517E-03 320 6,733E-02 5,774E-04
Eli 32,000 7,975E-02 3,786E-03 160 7,567E-02 1,155E-03
96Bw 8,000 7,000E-02 2,000E-03 320 6,567E-02 5,774E-04
CM240 16,000 7,150E-02 3,215E-03 320 6,733E-02 1,528E-03
HXB2 128,000 6,600E-02 3,606E-03 80 6,533E-02 5,774E-04
Aluminium Phosphate J90 Preimmune
titre mean SD titre mean SD
Oyi 32,000 6,900E-02 2,082E-03 320 6,800E-02 1,000E-03
Ug11RP 16,000 6,800E-02 2,082E-03 80 6,700E-02 1,414E-03
Eli 32,000 6,875E-02 2,646E-03 320 7,067E-02 1,528E-03
96Bw 8,000 6,875E-02 2,309E-03 160 7,367E-02 3,215E-03
CM240 16,000 7,075E-02 1,528E-03 160 7,433E-02 1,155E-03
HXB2 32,000 6,825E-02 2,309E-03 160 7,100E-02 2,646E-03
Titre corresponds to the reciprocal of the last positive dilution obtained by ELISA (cut-off : mean of preimmune sera + 3 S.D.)Retrovirology 2006, 3:8 http://www.retrovirology.com/content/3/1/8
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macaques were challenged with a European SHIV. This
was a heterologous SHIV challenge and no success in het-
erologous SHIV were published until now.
Results and discussion
We selected four adjuvants (Calcium phosphate, Monta-
nide, Adju-Phos and Alhydrogel) to develop different vac-
cine formulations with our synthetic protein Tat Oyi. The
usual dose of aluminium for human vaccines is around
0.5 mg [33] and at this concentration, approximately 90
% of 100 µg of Tat Oyi adsorbed to both aluminium con-
taining adjuvants (Adju-Phos and Alhydrogel). For these
two reasons, we decided to carry out our inoculations at
0.5 mg Al per dose of vaccine for both Adju-Phos and
Alhydrogel. For the calcium phosphate gel, we achieved
92 % adsorption using 1 mg Ca per 500 µl dose while only
62% adsorption using 0.5 mg Ca in the same volume.
Montanide adjuvant (70 %) was used because it is a
metabolizable oil that can be used for human vaccination
and has chemical properties similar to those found in the
Freund adjuvant as used in our first vaccination studies
[22].
Twelve rabbits were immunized with the four formula-
tions (three rabbits for each formulation) and we ana-
lyzed the antibody responses against five Tat variants
representative of subtypes A, B, C, D, and E (Table I). No
antibody response was observed using the calcium phos-
phate gel and the aluminium phosphate adjuvants at 60
days post-inoculation. However, at 90 days post-inocula-
tion, a strong antibody response was observed using these
two adjuvants against five Tat variants (Table I). The best
humoral response against Tat oyi was obtained using
Montanide ISA720 (titer: 128,000 against Tat Oyi) at both
60 and 90 days post-inoculation. However, Montanide
ISA720 and Calcium phosphate appear to be the most
suitable adjuvants to complement the synthetic protein
Tat Oyi, due to the absence of toxicity and the heterologu-
ous immunity compared with different Tat variants
observed after vaccination (Table I).
A heterologous SHIV-BX08 challenge carried out on seven
macaques vaccinated with Tat Oyi/Montanide ISA720
and four control macaques vaccinated with β-galactosi-
dase that were used also as control for another vaccine
trial [34]. Figure 1 shows the viremia as revealed by SHIV
RNA copy number in the sera of macaques after SHIV
challenge. Similarly to what is observed in human a cou-
ple of months after HIV infection, both Tat Oyi vaccinated
macaques and controls had an undetectable viremia 63
days after the SHIV challenge (Fig 1). In addition, virus
isolation and cytoviremia was measured by co-cultivation
of PBMC's with non-infected human cells at the day of
challenge and each week afterwards and allow to estimate
the level of reservoir cells (Fig 2). Five on seven Tat Oyi
Viral load of rhesus macaques vaccinated with Tat Oyi  (panel A) and control macaques vaccinated with β-gal  (panel B) following SHIV challenge (SHIV-BX08) Figure 1
Viral load of rhesus macaques vaccinated with Tat Oyi 
(panel A) and control macaques vaccinated with β-gal 
(panel B) following SHIV challenge (SHIV-BX08). The 965 
(white square), 966 (no symbol), 969 (black circle), 975 
(black square), 9611 (white circle), 9711 (white triangle) and 
9712 (black triangle) macaques are the Tat Oyi vaccinated 
macaques. The 963 (white square), 964 (black square), 978 
(white circle) and 9610 (black circle) Macaques are the con-
trols vaccinated with β-gal. Two vaccinated macaques (965 
and 969) on five had a viremia up to or superior to 1 millions 
RNA copies/ml that similar to controls. Macaque 966 had a 
viremia almost undetectable after the first SHIV challenge 
and remained at the same level in spite of a second challenge 
with SHIV 162P 3.2 seven weeks after the first challenge. The 
other macaques were not challenged twice. Control 
macaque 963 had an unexpected low viremia. Panel C: Grey 
bars indicate the post infection viremia in the plasma at two 
weeks and the black bars indicate viremia at nine weeks post-
infection of the challenged macaques. Macaque 966 has a 
higher viremia at nine weeks due to its second SHIV chal-
lenge.
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vaccinated macaques showed a better control of viremia
compared to control macaques (Fig 1). Reservoir cells
were not detectable at 56 days post-challenge in all Tat
Oyi vaccinated macaques but not in the controls (Fig. 2).
It has been shown in SHIV challenge that plasma viremia
in the first peak does not correlate with survival whereas
plasma viremia levels of the second peak at or about six
weeks post-infection were highly predictive of relative sur-
vival [35]. In our vaccine trial, panel C in figure 1 shows
that plasma viral RNA levels were significantly lower in
the vaccinated Macaques compared to the controls at nine
weeks post-infection (p = 0.009 using Mann-Whitney
test). While we did not observe major differences in the
level of CD4 cells between vaccinated and non vaccinated
macaques (data not shown), we did observe an augmen-
tation of the number of CD8 lymphocytes in Tat Oyi vac-
cinated macaques (Fig. 3). However, we did not
determine if these CD8 are HIV specific CTL. It is interest-
ing to observe that before the SHIV challenge, control
macaques had a higher level of CD8 compared to Tat Oyi
vaccinated macaques. Control macaques were immu-
nized with the Semliki Forest Virus (SFV) lac Z expressing
β-galactosidase that boost the CD8 response [34]. This
high level of CD8 were not HIV specific in control
macaques and they had no antibodies against Tat. There-
fore, we think that the decreased level of CD8+ cells in
control macaques after the SHIV challenge could be due
to extracellular Tat, since the SHIV infection should have
increased the CD8 response as observed for SFV.
All Tat-vaccinated macaques, with the exception of
Macaque 969, developed a strong anti-Tat antibody
response (Fig 4), which correlated with an efficient reduc-
tion in viremia at nine weeks post-infection (Fig 1C). This
was best demonstrated by monkey 965, which had a
strong anti-Tat antibody titer and a significantly reduced
viremia nine weeks post-infection despite a high viremia
in the primary phase (Fig 1C). To a lesser extent, macaque
9711 shows the same relationship between the level of
anti-Tat antibody and the viremia at nine weeks (Fig 1C).
Moreover, the control of viremia in Tat Oyi vaccinated
macaques was not due to antibodies raised against the
HIV envelope proteins since the four SHIV challenged
control macaques had high anti-gp120 antibody titers.
Overall, gp120 antibody titres were similar in control and
Tat Oyi vaccinated macaques (Fig 5).
Macaque 966 did react differently from the other Tat Oyi
vaccinated macaques and is the most interesting. It was
the one to have an almost complete immunity against
SHIV BX08 with a viremia peak around 300 RNA copies
per ml whilst most of the others macaques had viremia
peaks between 100 000 and 3 000 000 RNA copies per ml
(Fig 1). Interestingly, almost no antibodies against gp120
were detectable and no virus could be isolated from cul-
tured PBMC's (Fig 2). To verify this strong immunity,
macaque 966 was challenged a second time with another
heterologous SHIV 162P 3.2 seven weeks after the SHIV
BX08 challenge (Roger Legrand, Personal communica-
tion). This second challenge explains the higher viremia
peak at nine weeks post-infection compared to the other
Tat Oyi vaccinated macaques (Fig 1C), which rapidly
decreased to an undetectable level. It is interesting also to
note that antibodies against gp120 were observed with
macaque 966 following the second SHIV challenge that
also rapidly declined (Fig 5). Results observed with
macaque 966 are very important and constitute the best
proof of concept for the Tat Oyi vaccine and its rational as
previously described [22]. Macaque 966 had the highest
titer of anti-Tat antibody (Fig 4), the lowest viremia (Fig
2) and no detectable virus from cultured PBMCs (Fig 1).
Macaque 965 had nearly identical level of anti Tat anti-
HIV infected CD4 T cell (reservoir cells) in rhesus macaques  vaccinated with Tat Oyi (panel A) and control macaques  vaccinated with β-gal (panel B) following SHIV challenge Figure 2
HIV infected CD4 T cell (reservoir cells) in rhesus macaques 
vaccinated with Tat Oyi (panel A) and control macaques 
vaccinated with β-gal (panel B) following SHIV challenge. 
The 965 (white square), 966 (no symbol), 969 (black circle), 
975 (black square), 9611 (white circle), 9711 (white triangle) 
and 9712 (black triangle) Macaques are the Tat Oyi vacci-
nated Macaques. The 963 (white square), 964 (black square), 
978 (white circle) and 9610 (black circle) Macaques are the 
controls vaccinated with β-gal. The upper panel shows that 
no reservoir cells were detectable in the seven Tat Oyi vacci-
nated macaques after 56 days although macaques 965 and 
969 had high viremia peaks (Fig 1). Interestingly, no reservoir 
cells were detectable at any time for macaque 966 even after 
its second SHIV challenge.
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bodies but was not able to control its viremia as macaque
966. It is possible that innate immunity helped macaque
966, but it is interesting to note that antibodies against
gp120 disappeared rapidly for macaque 966 (Fig 5), sim-
ilarly to what was observed with the patients infected by
HIV-1 Oyi in Gabon [32] and HEPS patients [30].
Conflicting results appears in Tat vaccine studies in non-
human primate viral challenges models ranging from no
protection [34,36-38] to significant [39,24,25], long term
protection [26]. Although these conflicting results could
be explained by differences in immunization regimen,
viral stock, route of viral challenge and animal species, the
result of two studies using similar viral vector expressing
Tat, Env and Gag and giving opposite conclusion is puz-
zling [36,39]. One study shows the efficacy of vectored Tat
but not Gag and Env [39], while another study showed
efficacy of vectored Gag and Env but not Tat [36]. These
conflicting results could be due to a homologous chal-
lenge in the first study [39] and a heterologuous challenge
in the second study, since the second study use the Tat Jr
sequence instead of the homologuous Tat Bru sequence
for the vaccine [36]. HIV-1 Jr and HIV-1 Bru are B subtypes
but their Tat sequences have non conservative mutations
inducing conformational changes [16]. The mutations
between the vaccine and the challenge virus might explain
the lack of efficacy of the Tat vectored vaccine in the sec-
ond study [36]. Of course, the second study more closely
resembled reality since a vaccinated person will not likely
be exposed a homologous virus infection. It is possible
that the study by Silvera et al. would have had an different
outcome had heterologous gag and env genes been used in
the SHIV challenge [36]. These studies outline how muta-
tions can affect Tat cross recognition as shown in former
studies [22,27].
Conclusion
Three adjuvants authorized for human use trigger an
immune response with Tat Oyi similar to what was
observed with the complete Freund adjuvant in a former
study [22]. No local or systemic toxicity or adverse effects
were observed in rabbits and macaques with vaccine doses
superior to those planed for clinical trials. Furthermore,
the synthetic protein Tat Oyi is pharmacologically stable
in solution for at least a period of one month, which is a
requirement for mass vaccination (data not shown).
Although a low viremia was not achieved for all
macaques, reservoir cells were no longer detectable 56
days after a heterologuous challenge. Taken together,
these results suggest that a Tat Oyi synthetic protein could
be an excellent component of a vaccine targeting HIV-1
and could provide an appropriate treatment against HIV-
1 in both developing and industrial countries. On a fun-
damental point of view, the decreased level of CD8 cells
in the control macaques suggests an important role of
extra cellular Tat in the immunodeficiency induced by the
HIV-1. We hope to be able to confirm in phase I/II clinical
trial with seropositive patients that a therapeutical effect
can be obtained from the Tat Oyi vaccination. This thera-
peutic effect might result, firstly, in a reduced viremia and
stable CD4 cells level following an interruption of the
antiretroviral treatment. We believe this vaccine will not
prevent sero negative people from HIV infection, however
it could avoid the collapse of the cellular immunity, and
therefore a therapeutic effect could be expected with the
eradication of the virus titres and viral reservoir as is
observed with HEPS patients. This vaccine could be also
the only affordable therapy for millions of seropositive
patients that have no access to antiretroviral treatment.
Methods
Tat variants and adjuvant formulations
Tat variants were assembled in solid phase synthesis with
an ABI 433A peptide synthesizer with FASTMoc chemistry
according to the method of Barany and Merrifield [40] as
previously described [20,41]. The calcium Phosphate gel
adjuvant was obtained from Brenntag Biosector (Den-
CD8+ cell count of challenged Macaques Figure 3
CD8+ cell count of challenged Macaques. The 963, 964, 978 
and 9610 Macaques are the controls. The 965, 966, 969, 975, 
9611, 9711 and 9712 Macaques are the vaccinated Macaques. 
Striped histograms represent the CD8+ cell count at the day 
of challenge. Black histograms represent the CD8+ cell count 
9 weeks post-challenge whilst grey histograms represent the 
CD8+ cell count 18 weeks post-challenge.
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mark). The adjuvant based on a metabolizable oil with a
mannide mono-oleate emulsifier called Montanide
ISA720 was obtained from SEPPIC Ltd (Paris, France).
The two aluminum-containing adjuvants, aluminum
hydroxide (Alhydrogel 2 %, Superfos Biosector a/s,) and
aluminum phosphate (Adju-Phos, Superfos Biosector a/
s), were kindly provided by Vedbaeck (Denmark). Experi-
ments were conducted to assess the presence of soluble
antigen in the supernatant liquid of adsorbed experimen-
tal vaccines. Tat Oyi was added to the gel and gently
shaken for 24 h at room temperature. Samples were cen-
trifuged at 313 g for 15 min at room temperature. Super-
natant was aspirated and protein concentration was
determined using Bradford reagent. Protein adsorption by
aluminum-containing adjuvants was studied in 500 µl
suspensions containing a quantity of adjuvant equivalent
to 0.7, 0.5 or 0.3 mg Al.
Immunization protocols for rabbits and macaques
Twelve specific pathogen-free New Zealand rabbits (Ele-
vage Scientifique des Dombes, Romans, France) were
immunized with 100 µg of Tat Oyi and four different for-
mulations (three rabbits for each formulation): alumi-
num hydroxide (0.5 mg of Al) in phosphate buffer 20 mM
pH 6.5; aluminum phosphate (0.5 mg of Al) in sodium
acetate buffer 20 mM pH 6.5; calcium phosphate gel (1
mg of Ca) in phosphate buffer 20 mM pH 7; and Monta-
nide ISA720 (70%) in phosphate buffer 20 mM pH 6.5.
Each rabbit was boosted three times at 20, 40 and 75 days
after the first immunization. Sera were collected before
immunization, and then 60 and 90 days after the first
immunization. No death or injuries were observed during
or as a consequence of the immunization for the full time
of the experiment. The study on Macaques included
eleven rhesus macaques of Chinese origin. These
macaques were housed at the Primate Research Center at
Rennemoulins (Institut Pasteur, France) and handled
under ketamine hydrochloride anesthesia (Rhone-
Mérieux, Lyon, France) according to European guidelines
for animal care (Journal Officiel des Communautés
Européennes, L358, 18 décembre 1986). The animals
were checked to be virus-isolation negative, as well as
sero-negative for SIV and simian retrovirus type D before
entering the study. Seven macaques were immunized sub-
cutaneously with Tat Oyi (100 µg) and the adjuvant Mon-
tanide ISA 720. Boosts were given at 1, 2 and 3 months
after the first immunization. The control was four
macaques immunized with the Semliki Forest Virus lac Z
expressing β-galactosidase [34]. No death or injuries were
observed during or as a consequence of the immunization
for the full time of the experiment.
SHIV challenge
The seven macaques vaccinated with Tat Oyi were
included in a SHIV challenge assay called RIVAC spon-
sored by the ANRS. The purpose of the RIVAC assay was
to compare ten vaccine approaches on five to seven
macaques with the same SHIV challenge model. Only
results obtained with three vaccine approaches have been
published [34]. The challenge strain was SHIV-BX08,
derived from SIVmac239 [34]. This is a hybrid virus
expressing the gp120 subunit of the R5, clade B, primary
HIV-1 isolate BX08 and the gp41 subunit of HIV-1 LAI
[42]. The tat and rev genes are also from HIV-LAI, whereas
the gag, pol, vif, vpx and nef genes are from SIVmac239. The
animals were challenged intra-rectally (IR) seven months
after the first immunization. The virus stock used for chal-
lenge was amplified on human PBMC and 10-fold serial
dilutions where used for inoculation of rhesus macaques.
The undiluted challenge dose contained 337 +/- 331
AID50 for IR administration, as determined by the method
of Spouge [43]. Tat vaccinated and control animals were
sedated with ketamine hydrochloride (10 mg/kg i.m.)
Antibody response against Tat for the seven macaques vacci- nated with Tat Oyi Figure 4
Antibody response against Tat for the seven macaques vacci-
nated with Tat Oyi. The 965 (white square), 966 (no sym-
bol), 969 (black circle), 975 (black square), 9611 (white 
circle), 9711 (white triangle) and 9712 (black triangle) 
Macaques are the Tat Oyi vaccinated Macaques. Macaque 
966 in the top had the best response against Tat and turned 
to have the best control of the viremia with no reservoir 
cells detected (Fig 1 & 2). The left axis shows the OD of 1/
100 sera dilution.
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Serological tests
ELISA were carried out as previously described [22] with a
minor change. Maxisorp U96 immunoplates (Nunc) were
coated with 100 µl of Tat Oyi diluted at 2,3 µg/ml in phos-
phate buffer 100 mM pH 6 overnight at 4°C. This experi-
ment was repeated three times.
HIV infected CD4 T cell or reservoir cell count
Reservoir cells counts was carried out with the cell-associ-
ated viral load method [44]. Virus isolation was carried
out by co-cultivation of macaque PBMC with PHA-stimu-
lated human (donor) PBMC. Viral RNA was extracted
from 200 µl of plasma collected on EDTA using the High
Pure RNA Kit from Roche (Mannheim, Germany) and
stored frozen at -80°C. 10 µl of the extracted material
were then submitted to reverse transcription and PCR for
amplification as described previously [34].
Cell count
Counting of CD4+, CD8+, CD3+ and CD20+ cells was per-
formed as described previously [45].
Statistical analysis
Statistical analysis of serological data was carried out
using the Mann-Whitney test or one-way Anova test using
Minitab Release 14. We considered that the difference
between two samples was significant if the P-value was
less than 0.05.
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